Pharmacoeconomic Evaluation of Four Short-term Triple Therapeutic Schemes for Eradicating Hp
- VernacularTitle:4组短程三联方案根除幽门螺杆菌的药物经济学评价
- Author:
Huafeng CHENG
;
Huiming CAO
;
Qian CHEN
;
Nansen ZHANG
- Publication Type:Journal Article
- Keywords:
Helicobacter pylori;
pharmocoeconomics;
eradication;
triple therapy;
cost-effectiveness analysis
- From:
China Pharmacy
1991;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:Four different one-week triple therapeutic schemes to eradicate Helicobacter pylori were compared by pharmacoeconomic analysis to provide a scientific method for rational assignment of our limited medical fund.METHODS:According to literature reports,892 cases of duodenal ulcer and gastritis with Helicobacter pylori were selected.These patients were randomly divided into four groups which received different one-week triple therapeutic schemes:OMC(Omeprazole+Metronidazole+Clarithromycin),OFC(Omeprazole+Furazolidone+Clarithromycin),OFA(Omeprazole+Furazolidone+Amoxicillin)and BFC(Colloidal bismuth subcitrate+Furazolidone+Clarithromycin).The schemes were evaluated with pharmacoeconomic cost-effectiveness analysis.RESULTS:The cost-effectiveness ratios of OMC,OFC,OFA,BFC for gastritis or duodenal ulcer were 16.19/17.33,17.30/13.93,11.40/10.56,11.17/10.75 respectively.They changed to 16.36/17.51,17.49/14.08,8.15/7.55,11.66/11.20 by sensitivity analysis.CONCLUSION:OFA is the most effective and inexpensive one to era_dicate Hp.
